Effect of Siddha medicine Sangu Parpam in the treatment of Eye disease-Blurred vision (Kan pugaichal)

A Pilot Study to explore the Effectiveness of Siddha formulation Sangu parpam in the management of Age-Related Macular Degeneration (Kan pugaichal) - Nil

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/11/059442

Enrollment

Registered

2023-11-02

Start date

Unknown

Completion date

Unknown

Last updated

2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H353- Degeneration of macula and posterior pole

Interventions

Intervention1: Sangu parpam: 2 tablets(Internal) with Ghee twice a day 48 days Control Intervention1: NA: NA

Eligibility

Inclusion criteria

Inclusion criteria: Patients diagnosed with age-related macular degeneration

Exclusion criteria

Exclusion criteria: Priror use of any prohibhited medication(s)of procedure(s) within the specified timeframe for the treatment of age-related macular degeneration Use of anticholinergic agents within 15 days of the baseline visit Any other condition including psychiatric illness (Depression or anxiety) Patients diagnosed with diabetic retinopathy and cataract End stage renal diseases and liver disorders

Design outcomes

Primary

Measure	Time frame
This study will discover the therapeutic effectiveness of Siddha herbo mineral formulation Sangu parpam in age-related macular DegenerationTimepoint: 48 days	—

Secondary

Measure	Time frame
Reduction and improvement in th equality of life in Age-realted macular degeneration patients through Impact of Vision Impairment QuestionnarieTimepoint: 48 days	—

Countries

India

Contacts

Public ContactDr R Devaki

National Institute of Siddha

drdevakimd@gmail.com9344232461

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026